Cardiogen
Research OnlyAlso known as: AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Research Statistics
Russian-only bioregulator; cardiac peptide with no independent Western replication.
Research Dossier
Overview
What is Cardiogen and what does the research say?
Mechanism of Action
The proposed mechanisms of Cardiogen are based exclusively on Russian research. No independent Western validation exists, and human mechanistic data from controlled trials is entirely lacking.
How It Works (Simplified)
Cardiogen targets cardiac tissue through several proposed pathways:
Claimed to penetrate cells and interact with DNA in cardiomyocytes, influencing cardiac-specific gene transcription and protein synthesis.
Proposed to enhance cardiac antioxidant enzyme activity, reducing oxidative stress and protecting against ischemic damage.
Suggested to promote cardiomyocyte survival and support tissue repair processes following cardiac injury.
Claimed to reduce pathological fibrosis by inhibiting cardiac fibroblast activation and excessive collagen deposition.
Scientific Pathways
Gene Expression Pathway (Cardiac Function)
Cardiogen → Cell Membrane Penetration → Nuclear Localization
↓
DNA Binding (Promoter Regions)
↓
Cardiac Gene Transcription Modulation
↓
Cardiomyocyte Protein SynthesisCardioprotective Pathway (Oxidative Stress)
Cardiogen → Antioxidant Enzyme Upregulation (SOD, Catalase)
↓
Reduced Reactive Oxygen Species (ROS)
↓
Protection Against Ischemic/Oxidative DamageKey Research Context: Khavinson’s bioregulation theory proposes that short peptides can penetrate cells and interact with specific DNA sequences to modulate gene expression in a tissue-specific manner. Cardiogen is claimed to be specific to cardiac tissue.
Important Limitations
- 100% of research originates from Russian institutions affiliated with Khavinson
- No independent Western laboratories have studied cardiogen
- No randomized controlled clinical trials in any population
- Human “studies” are limited to uncontrolled observational reports
- Mechanism of selective cardiac targeting is not characterized
- Pharmacokinetics, bioavailability, and optimal dosing unknown
- Translation from cell culture/animal models to human cardiac benefit is unconfirmed
- Should not replace standard evidence-based cardiac care
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: Initial peptide-DNA interactions and gene expression changes may begin in cardiac tissue. Russian protocols typically start effects assessment at this point.
Continued treatment may produce measurable changes in cardiac biomarkers based on animal model timelines. Antioxidant effects observed in preclinical studies within this window.
Russian protocols often use treatment periods of 10-20 days with rest intervals. Functional cardiac improvements reported in animal studies at this duration.
Long-term effects based on Russian observational studies in elderly patients. Cyclical treatment protocols are typical. Human pharmacokinetics and optimal duration are unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Cardiogen product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Cardiogen with other peptides. Based on published research and mechanistic considerations.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct tissue targets - epithalon for pineal/telomeres, cardiogen for cardiac tissue. No known direct interactions.
Thymalin
CompatibleBoth Russian peptide bioregulators - thymalin for thymus/immune modulation, cardiogen for cardiac support. May be used in combination protocols.
BPC-157
CompatibleDifferent cardioprotective mechanisms - BPC-157 provides systemic tissue healing and NO pathway modulation, cardiogen targets cardiac-specific gene expression.
GHK-Cu
CompatibleComplementary regenerative targets - GHK-Cu for extracellular matrix remodeling, cardiogen for cardiomyocyte-specific effects.
Ss-31
CompatibleDifferent cardiac support mechanisms - SS-31 targets mitochondrial function and cardiolipin, cardiogen targets gene expression in heart tissue.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Cardiogen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.
Livagen
KED, Lys-Glu-Asp, Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.